{"id":130335,"date":"2021-08-23T17:00:00","date_gmt":"2021-08-23T17:00:00","guid":{"rendered":"https:\/\/icrowdnewswire.com\/?p=2903963"},"modified":"2021-08-23T17:00:00","modified_gmt":"2021-08-23T17:00:00","slug":"key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2021\/08\/23\/key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market\/","title":{"rendered":"Key players such as Phathom Pharmaceuticals and others are developing therapies to enhance treatment modalities in the Zollinger-Ellison Syndrome market"},"content":{"rendered":"<p><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/5353-new20logo-01-3.png\" class=\"webfeedsFeaturedVisual wp-post-image\" alt=\"\" loading=\"lazy\" style=\"display: block; margin-bottom: 5px; clear:both;max-width: 100%;\" link_thumbnail=\"\" \/><\/p>\n<p><span style=\"font-weight: 400;\"><img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/beta-kiosk.icrowdnewswire.com\/assets\/source\/users\/delveinsight\/Zollinger-Ellison-Syndrome-Market-Insights.jpg?1629698704357\" alt=\"Zollinger-Ellison-Syndrome-Market-Insights\" width=\"697\" height=\"423\" \/><\/span><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsigth&rsquo;s <\/span><a href=\"https:\/\/www.delveinsight.com\/report-store\/zollinger-ellison-syndrome-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"noopener\"><strong>Zollinger-Ellison Syndrome market report<\/strong><\/a><span style=\"font-weight: 400;\"> provides an in-depth understanding of the Zollinger-Ellison Syndrome, historical and forecasted epidemiology, as well as Zollinger-Ellison Syndrome market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan).&nbsp;<\/span><\/p>\n<p><strong>Some of the Key Highlights from the <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/zollinger-ellison-syndrome-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"noopener\"><strong>Zollinger-Ellison Syndrome Market Report<\/strong><\/a><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">According to NIDDK, Zollinger-Ellison Syndrome is extremely rare. It affects <\/span><strong>one in a million<\/strong><span style=\"font-weight: 400;\"> people globally. It is more common in men than in women and usually occurs between the ages of 30 and 50.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">In the United States, approximately<\/span><strong> 0.1-1 percent<\/strong><span style=\"font-weight: 400;\"> of all patients with duodenal ulcers have Zollinger-Ellison Syndrome (ZES).<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Key players such as <\/span><strong>Phathom Pharmaceuticals <\/strong><span style=\"font-weight: 400;\">and others are diligently working toward the development of novel therapies for Zollinger-Ellison Treatment.<\/span><\/li>\n<li style=\"font-weight: 400;\"><strong>Vonoprazan (Phathom Pharmaceuticals)<\/strong><span style=\"font-weight: 400;\">, is a late-stage investigational potassium competitive acid blocker (P-CAB) for the treatment of gastric acid-related disorders.&nbsp;<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">For a better understanding of the disease, request sample @<\/span><a href=\"https:\/\/www.delveinsight.com\/sample-request\/zollinger-ellison-syndrome-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"noopener\"> <strong>Zollinger-Ellison Syndrome Symptoms, Diagnosis and Therapy<\/strong><\/a><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/zollinger-ellison-syndrome-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"noopener\"><strong>The Zollinger-Ellison Syndrome market report<\/strong><\/a><span style=\"font-weight: 400;\"> covers current treatment practices, emerging drugs, Zollinger-Ellison Syndrome market share of individual therapies, as well as current and forecasted Zollinger-Ellison Syndrome market Size from 2018 to 2030, segmented by seven major markets.<\/span><\/p>\n<p><strong>Zollinger-Ellison Syndrome: Overview<\/strong><\/p>\n<p><span style=\"font-weight: 400;\">The Zollinger-Ellison Syndrome (ZES) is characterized by the development of a tumor (gastrinoma) or tumors that secrete excessive amounts of gastrin, a hormone that stimulates the stomach&#8217;s acid production. Many people who are affected develop multiple gastrinomas, which are thought to be cancerous (malignant). The majority of patients&#8217; tumors develop in the pancreas and\/or the upper region of the small intestine (duodenum). Individuals with ZES may develop peptic ulcers of the stomach, duodenum, and\/or other regions of the digestive tract as a result of excessive acid production (gastric acid hypersecretion).<\/span><\/p>\n<p><strong>Zollinger-Ellison Syndrome Epidemiology Segmentation<\/strong><\/p>\n<p><span style=\"font-weight: 400;\">The Zollinger-Ellison Syndrome report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Zollinger-Ellison Syndrome Incident Cases<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Zollinger-Ellison Syndrome Gender-Specific Cases<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Zollinger-Ellison Syndrome Age-Specific Cases<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Zollinger-Ellison Syndrome Diagnosed and Treated Cases<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Get the complete epidemiology analysis @ <\/span><a href=\"https:\/\/www.delveinsight.com\/report-store\/zollinger-ellison-syndrome-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"noopener\"><strong>Zollinger-Ellison Syndrome Risk Factors<\/strong><\/a><\/p>\n<p><strong>Zollinger-Ellison Syndrome Treatment Landscape<\/strong><\/p>\n<p><span style=\"font-weight: 400;\">The Zollinger-Ellison syndrome (ZES) treatment goals are medical control of gastric acid hypersecretion and surgical resection of the tumor. Proton Pump Inhibitors (PPIs) drugs that are used to reduce stomach acid production and allow ulcers to heal include<\/span><strong> lansoprazole (Prevacid), omeprazole (Prilosec, Zegerid), pantoprazole (Protonix), dexlansoprazole (Dexilant), esomeprazole (Nexium), and rabeprazole (Aciphex). <\/strong><span style=\"font-weight: 400;\">For patients with advanced cancer, a combination of therapies such as <\/span><strong>surgery, chemotherapy, Octreotide (Sandostatin), targeted drug therapy, or radiation<\/strong><span style=\"font-weight: 400;\"> may be beneficial.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/zollinger-ellison-syndrome-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"noopener\"><strong>Zollinger-Ellison Syndrome Market<\/strong><\/a><strong>&nbsp;<\/strong><\/p>\n<p><span style=\"font-weight: 400;\">Extensive research and development activities by pharmaceutical companies such as <\/span><strong>Phathom Pharmaceuticals<\/strong><span style=\"font-weight: 400;\">, as well as the anticipated launch of approved therapies such as <\/span><strong>Vonoprazan<\/strong><span style=\"font-weight: 400;\"> and others will drive Zollinger-Ellison Syndrome market growth during the forecast period, i.e., 2021&ndash;2030.<\/span><\/p>\n<p><strong>Zollinger-Ellison Syndrome Pipeline Therapies and Key Companies&nbsp;<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Vonoprazan: Phathom Pharmaceuticals<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">For further information on the emerging drugs, visit <\/span><a href=\"https:\/\/www.delveinsight.com\/report-store\/zollinger-ellison-syndrome-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"noopener\"><strong>Zollinger-Ellison Syndrome Treatment Drugs<\/strong><\/a><\/p>\n<p><strong>Table of Contents&nbsp;<\/strong><\/p>\n<table style=\"border-collapse: collapse; width: 100%;\" border=\"1\">\n<tbody>\n<tr style=\"height: 17px;\">\n<td style=\"width: 9.21569%; height: 17px;\">1.<\/td>\n<td style=\"width: 90.7843%; height: 17px;\"><span style=\"font-weight: 400;\">Key Insights<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"width: 9.21569%; height: 17px;\">2.<\/td>\n<td style=\"width: 90.7843%; height: 17px;\"><span style=\"font-weight: 400;\">Zollinger-Ellison Syndrome (ZES) Market Overview at a Glance<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"width: 9.21569%; height: 17px;\">3.<\/td>\n<td style=\"width: 90.7843%; height: 17px;\"><span style=\"font-weight: 400;\">Executive summary<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"width: 9.21569%; height: 17px;\">4.<\/td>\n<td style=\"width: 90.7843%; height: 17px;\"><span style=\"font-weight: 400;\">Organizations<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"width: 9.21569%; height: 17px;\">5.<\/td>\n<td style=\"width: 90.7843%; height: 17px;\"><span style=\"font-weight: 400;\">Disease Overview: Zollinger-Ellison Syndrome (ZES)<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"width: 9.21569%; height: 17px;\">6.<\/td>\n<td style=\"width: 90.7843%; height: 17px;\"><span style=\"font-weight: 400;\">Zollinger-Ellison Syndrome Epidemiology and Patient Population<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"width: 9.21569%; height: 17px;\">7.<\/td>\n<td style=\"width: 90.7843%; height: 17px;\"><span style=\"font-weight: 400;\">Zollinger-Ellison Syndrome Current Treatment Practices<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"width: 9.21569%; height: 17px;\">8.<\/td>\n<td style=\"width: 90.7843%; height: 17px;\"><span style=\"font-weight: 400;\">Zollinger-Ellison Syndrome Unmet Needs<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"width: 9.21569%; height: 17px;\">9.<\/td>\n<td style=\"width: 90.7843%; height: 17px;\"><span style=\"font-weight: 400;\">Zollinger-Ellison Syndrome Marketed Drugs<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"width: 9.21569%; height: 17px;\">10.<\/td>\n<td style=\"width: 90.7843%; height: 17px;\"><span style=\"font-weight: 400;\">Zollinger-Ellison Syndrome Emerging Therapies<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"width: 9.21569%; height: 17px;\">11.<\/td>\n<td style=\"width: 90.7843%; height: 17px;\"><span style=\"font-weight: 400;\">Zollinger-Ellison Syndrome (ZES): 7MM Analysis<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"width: 9.21569%; height: 17px;\">12.<\/td>\n<td style=\"width: 90.7843%; height: 17px;\"><span style=\"font-weight: 400;\">Zollinger-Ellison Syndrome Market Drivers<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"width: 9.21569%; height: 17px;\">13.<\/td>\n<td style=\"width: 90.7843%; height: 17px;\"><span style=\"font-weight: 400;\">Zollinger-Ellison Syndrome Market Barriers<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"width: 9.21569%; height: 17px;\">14.<\/td>\n<td style=\"width: 90.7843%; height: 17px;\"><span style=\"font-weight: 400;\">Zollinger-Ellison Syndrome Market Access and Reimbursement<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"width: 9.21569%; height: 17px;\">15.<\/td>\n<td style=\"width: 90.7843%; height: 17px;\"><span style=\"font-weight: 400;\">SWOT Analysis<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"width: 9.21569%; height: 17px;\">16.<\/td>\n<td style=\"width: 90.7843%; height: 17px;\"><span style=\"font-weight: 400;\">Case studies<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"width: 9.21569%; height: 17px;\">17.<\/td>\n<td style=\"width: 90.7843%; height: 17px;\"><span style=\"font-weight: 400;\">KOL Views<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"width: 9.21569%; height: 17px;\">18.<\/td>\n<td style=\"width: 90.7843%; height: 17px;\"><span style=\"font-weight: 400;\">Appendix<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"width: 9.21569%; height: 17px;\">19.<\/td>\n<td style=\"width: 90.7843%; height: 17px;\"><span style=\"font-weight: 400;\">DelveInsight Capabilities<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"width: 9.21569%; height: 17px;\">20.<\/td>\n<td style=\"width: 90.7843%; height: 17px;\"><span style=\"font-weight: 400;\">Disclaimer<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"width: 9.21569%; height: 17px;\">21.<\/td>\n<td style=\"width: 90.7843%; height: 17px;\"><span style=\"font-weight: 400;\">About DelveInsight<\/span><\/td>\n<\/tr>\n<tr style=\"height: 17px;\">\n<td style=\"width: 9.21569%; height: 17px;\">22.<\/td>\n<td style=\"width: 90.7843%; height: 17px;\"><span style=\"font-weight: 400;\">Disclaimer<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-weight: 400;\">Know more about report offerings @ <\/span><a href=\"https:\/\/www.delveinsight.com\/sample-request\/zollinger-ellison-syndrome-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"noopener\"><strong>Zollinger-Ellison Syndrome Market Size<\/strong><\/a><\/p>\n<p><strong>Related Reports<\/strong><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/alagille-syndrome-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"noopener\"><strong>Alagille Syndrome Market<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">Get comprehensive historical and forecast analysis of <\/span><span style=\"font-weight: 400;\">Alagille Syndrome<\/span><span style=\"font-weight: 400;\"> Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as <\/span><strong>Mirum Pharmaceuticals, Albireo,<\/strong><span style=\"font-weight: 400;\"> among others.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/sample-request\/fragile-x-syndrome-fxs-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"noopener\"><strong>Fragile X Syndrome Market<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">Get comprehensive historical and forecast analysis of <\/span><span style=\"font-weight: 400;\">Fragile X Syndrome<\/span><span style=\"font-weight: 400;\"> Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as <\/span><strong>Neuren Pharmaceuticals, Ovid Therapeutics, Tetra Therapeutics,&nbsp; Confluence Pharmaceuticals, Zynerba Pharmaceuticals,<\/strong><span style=\"font-weight: 400;\"> among others.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-bone-pain-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"noopener\"><strong>Metastatic Bone Pain Market<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&#8217;s<\/span><strong> &#8220;Metastatic Bone Pain &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221; <\/strong><span style=\"font-weight: 400;\">report.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-melanoma-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"noopener\"><strong>Metastatic Melanoma Market<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&#8217;s <\/span><strong>&#8220;Metastatic Melanoma &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221;<\/strong><span style=\"font-weight: 400;\"> report.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/alport-syndrome-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"noopener\"><strong>Alport Syndrome Market<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&#8217;s <\/span><strong>&#8220;Alport Syndrome &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221;<\/strong><span style=\"font-weight: 400;\"> report delivers an in-depth understanding of the Alport Syndrome, historical and forecasted epidemiology as well as the Alport Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n<p><a href=\"http:\/\/delveinsight.com\/report-store\/acute-myeloid-leukemia-aml-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"noopener\"><strong>Acute Myeloid Leukemia Market<\/strong><span style=\"font-weight: 400;\">&nbsp;<\/span><\/a><\/p>\n<p><span style=\"font-weight: 400;\">Get comprehensive historical and forecast analysis of <\/span><span style=\"font-weight: 400;\">Acute Myeloid Leukemia<\/span><span style=\"font-weight: 400;\"> Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as <\/span><strong>Pfizer, Abbvie, Astellas Pharma,<\/strong><span style=\"font-weight: 400;\"> among others.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/sample-request\/multiple-myeloma-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"noopener\"><strong>Multiple Myeloma<\/strong><strong> Market<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">Get comprehensive historical and forecast analysis of <\/span><span style=\"font-weight: 400;\">Multiple Myeloma<\/span><span style=\"font-weight: 400;\"> Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as <\/span><strong>Johnson &amp; Johnson, Amgen,&nbsp; BioLineRx, Bristol-Myers Squibb, ExCellThera, Pfizer,&nbsp; Takeda, Precision BioSciences,&nbsp; Poseida Therapeutics,<\/strong><span style=\"font-weight: 400;\"> among others.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/sample-request\/friedreichs-ataxia-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"noopener\"><strong>Friedreich&#8217;s Ataxia Market<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&#8217;s <\/span><strong>&#8220;Friedreich&#8217;s Ataxia &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221;<\/strong><span style=\"font-weight: 400;\"> report delivers an in-depth understanding of the Friedreich&#8217;s Ataxia, historical and forecasted epidemiology as well as the Friedreich&#8217;s Ataxia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-colorectal-cancer-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"noopener\"><strong>Metastatic Colorectal Cancer Market<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">Get comprehensive historical and forecast analysis of Metastatic Colorectal Cancer Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as <\/span><strong>Merck, Eli Lilly, Bristol-Myers Squibb, Amgen, Taiho Oncology, Pfizer, Isofol Medical, Ab Science, Effector Therapeutics, Vaximm, Cardiff Oncology,<\/strong><span style=\"font-weight: 400;\"> others.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/dravet-syndrome-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"noopener\"><strong>Dravet Syndrome<\/strong><strong> Market<\/strong><span style=\"font-weight: 400;\">&nbsp;<\/span><\/a><\/p>\n<p><span style=\"font-weight: 400;\">Get comprehensive historical and forecast analysis of <\/span><span style=\"font-weight: 400;\">Dravet Syndrome<\/span><span style=\"font-weight: 400;\"> Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as <\/span><strong>Biocodex, GW Pharmaceuticals, Zogenix, Ovid Therapeutics, PTC Therapeutics,<\/strong><span style=\"font-weight: 400;\"> among others.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/consulting\/market-assessment-services?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"noopener\"><strong>For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">About<\/span><a href=\"https:\/\/www.delveinsight.com\/?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"noopener\"> <strong>DelveInsight<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp;<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform<\/span><a href=\"https:\/\/www.pharmdelve.com\/?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=spr\" target=\"_blank\" rel=\"noopener\"> <strong>PharmDelve<\/strong><span style=\"font-weight: 400;\">.<\/span><\/a><\/p>\n<p><strong>Contact Us&nbsp;<\/strong><\/p>\n<p><span style=\"font-weight: 400;\">Sandeep Joshi&nbsp;<\/span><\/p>\n<p><span style=\"font-weight: 400;\">info@delveinsight.com&nbsp;<\/span><\/p>\n<p><span style=\"font-weight: 400;\">+1(919)321-6187&nbsp;<\/span><\/p>\n<p><a href=\"http:\/\/www.delveinsight.com\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">www.delveinsight.com<\/span><\/a><\/p>\n<p><strong>Connect With Us at:<\/strong><\/p>\n<p><a href=\"https:\/\/www.linkedin.com\/company\/delveinsight-business-research-llp\/\" target=\"_blank\" rel=\"noopener\"><strong>LinkedIn<\/strong><\/a> <strong>|<\/strong><a href=\"https:\/\/www.facebook.com\/delveinsightindia\/\" target=\"_blank\" rel=\"noopener\"> <strong>Facebook<\/strong><\/a> <strong>|<\/strong><a href=\"https:\/\/twitter.com\/delve_insight\" target=\"_blank\" rel=\"noopener\"> <strong>Twitter<\/strong><\/a><\/p>\n<p class=\"tags\">Tags: <a href=\"https:\/\/icrowdnewswire.com\/tag\/zollinger-ellison-syndrome-risk-factors\/\" rel=\"tag noopener\" target=\"_blank\">Zollinger-Ellison Syndrome Risk Factors<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/zollinger-ellison-syndrome-casuses\/\" rel=\"tag noopener\" target=\"_blank\">Zollinger- Ellison Syndrome Casuses<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/zollinger-ellison-syndrome-treatment-drug\/\" rel=\"tag noopener\" target=\"_blank\">Zollinger-Ellison Syndrome Treatment Drug<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/zollinger-ellison-syndrome\/\" rel=\"tag noopener\" target=\"_blank\">Zollinger-Ellison Syndrome<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/zollinger-ellison-syndrome-symptoms\/\" rel=\"tag noopener\" target=\"_blank\">Zollinger-Ellison Syndrome Symptoms<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/zollinger-ellison-syndrome-diagnostic-tests\/\" rel=\"tag noopener\" target=\"_blank\">Zollinger-Ellison Syndrome Diagnostic Tests<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/zollinger-ellison-syndrome-market-size\/\" rel=\"tag noopener\" target=\"_blank\">Zollinger-Ellison Syndrome Market Size<\/a> <\/p>\n<div><strong>See Campaign: <\/strong><a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.delveinsight.com\/<\/a><br \/><b>Contact Information:<\/b><br \/>Sandeep Joshi\u00a0 info@delveinsight.com\u00a0 +1(919)321-6187<\/p>\n<p><b>Tags:<\/b><br \/><a href=\"https:\/\/icrowdnewswire.com\/category\/menafn\/\" rel=\"category tag noopener\" target=\"_blank\">Menafn<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/ips\/\" rel=\"category tag noopener\" target=\"_blank\">IPS<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/reportedtimes\/\" rel=\"category tag noopener\" target=\"_blank\">Reportedtimes<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/pr-wirein\/\" rel=\"category tag noopener\" target=\"_blank\">PR-Wirein<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/extended-distribution\/\" rel=\"category tag noopener\" target=\"_blank\">Extended Distribution<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/icn-internal-distribution\/\" rel=\"category tag noopener\" target=\"_blank\">iCN Internal Distribution<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/research-newswire\/\" rel=\"category tag noopener\" target=\"_blank\">Research Newswire<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/language\/english\/\" rel=\"category tag noopener\" target=\"_blank\">English<\/a><\/p>\n<\/div>\n<div>\n<h3>Contact Information:<\/h3>\n<p>Sandeep Joshi\u00a0<\/p>\n<p> info@delveinsight.com\u00a0<\/p>\n<p> +1(919)321-6187<\/p>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsigth&rsquo;s Zollinger-Ellison Syndrome market report provides an in-depth understanding of the Zollinger-Ellison Syndrome, historical and forecasted epidemiology, as well as Zollinger-Ellison Syndrome market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan).&nbsp; Some of the Key Highlights from the Zollinger-Ellison Syndrome Market Report According to NIDDK, Zollinger-Ellison [&hellip;] <a href=\"https:\/\/ipsnews.net\/business\/2021\/08\/23\/key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market\/\" class=\"more-link\">Continue Reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":291,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-130335","post","type-post","status-publish","format-standard","hentry","category-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Key players such as Phathom Pharmaceuticals and others are developing therapies to enhance treatment modalities in the Zollinger-Ellison Syndrome market - Business<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/ipsnews.net\/business\/2021\/08\/23\/key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Key players such as Phathom Pharmaceuticals and others are developing therapies to enhance treatment modalities in the Zollinger-Ellison Syndrome market - Business\" \/>\n<meta property=\"og:description\" content=\"DelveInsigth&rsquo;s Zollinger-Ellison Syndrome market report provides an in-depth understanding of the Zollinger-Ellison Syndrome, historical and forecasted epidemiology, as well as Zollinger-Ellison Syndrome market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan).&nbsp; Some of the Key Highlights from the Zollinger-Ellison Syndrome Market Report According to NIDDK, Zollinger-Ellison [&hellip;] Continue Reading &rarr;\" \/>\n<meta property=\"og:url\" content=\"http:\/\/ipsnews.net\/business\/2021\/08\/23\/key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market\/\" \/>\n<meta property=\"og:site_name\" content=\"Business\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-23T17:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/5353-new20logo-01-3.png\" \/>\n<meta name=\"author\" content=\"iCrowdNewswire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"iCrowdNewswire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/08\/23\/key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market\/\",\"url\":\"http:\/\/ipsnews.net\/business\/2021\/08\/23\/key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market\/\",\"name\":\"Key players such as Phathom Pharmaceuticals and others are developing therapies to enhance treatment modalities in the Zollinger-Ellison Syndrome market - Business\",\"isPartOf\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#website\"},\"primaryImageOfPage\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/08\/23\/key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market\/#primaryimage\"},\"image\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/08\/23\/key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/5353-new20logo-01-3.png\",\"datePublished\":\"2021-08-23T17:00:00+00:00\",\"author\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\"},\"breadcrumb\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/08\/23\/key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/ipsnews.net\/business\/2021\/08\/23\/key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/08\/23\/key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market\/#primaryimage\",\"url\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/5353-new20logo-01-3.png\",\"contentUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/5353-new20logo-01-3.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/08\/23\/key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ipsnews.net\/business\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Key players such as Phathom Pharmaceuticals and others are developing therapies to enhance treatment modalities in the Zollinger-Ellison Syndrome market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ipsnews.net\/business\/#website\",\"url\":\"https:\/\/ipsnews.net\/business\/\",\"name\":\"Business\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ipsnews.net\/business\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\",\"name\":\"iCrowdNewswire\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"caption\":\"iCrowdNewswire\"},\"sameAs\":[\"https:\/\/heymuse.com\/ips\"],\"url\":\"https:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Key players such as Phathom Pharmaceuticals and others are developing therapies to enhance treatment modalities in the Zollinger-Ellison Syndrome market - Business","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/ipsnews.net\/business\/2021\/08\/23\/key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market\/","og_locale":"en_US","og_type":"article","og_title":"Key players such as Phathom Pharmaceuticals and others are developing therapies to enhance treatment modalities in the Zollinger-Ellison Syndrome market - Business","og_description":"DelveInsigth&rsquo;s Zollinger-Ellison Syndrome market report provides an in-depth understanding of the Zollinger-Ellison Syndrome, historical and forecasted epidemiology, as well as Zollinger-Ellison Syndrome market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan).&nbsp; Some of the Key Highlights from the Zollinger-Ellison Syndrome Market Report According to NIDDK, Zollinger-Ellison [&hellip;] Continue Reading &rarr;","og_url":"http:\/\/ipsnews.net\/business\/2021\/08\/23\/key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market\/","og_site_name":"Business","article_published_time":"2021-08-23T17:00:00+00:00","og_image":[{"url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/5353-new20logo-01-3.png","type":"","width":"","height":""}],"author":"iCrowdNewswire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"iCrowdNewswire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/ipsnews.net\/business\/2021\/08\/23\/key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market\/","url":"http:\/\/ipsnews.net\/business\/2021\/08\/23\/key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market\/","name":"Key players such as Phathom Pharmaceuticals and others are developing therapies to enhance treatment modalities in the Zollinger-Ellison Syndrome market - Business","isPartOf":{"@id":"https:\/\/ipsnews.net\/business\/#website"},"primaryImageOfPage":{"@id":"http:\/\/ipsnews.net\/business\/2021\/08\/23\/key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market\/#primaryimage"},"image":{"@id":"http:\/\/ipsnews.net\/business\/2021\/08\/23\/key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market\/#primaryimage"},"thumbnailUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/5353-new20logo-01-3.png","datePublished":"2021-08-23T17:00:00+00:00","author":{"@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee"},"breadcrumb":{"@id":"http:\/\/ipsnews.net\/business\/2021\/08\/23\/key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/ipsnews.net\/business\/2021\/08\/23\/key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/ipsnews.net\/business\/2021\/08\/23\/key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market\/#primaryimage","url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/5353-new20logo-01-3.png","contentUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/5353-new20logo-01-3.png"},{"@type":"BreadcrumbList","@id":"http:\/\/ipsnews.net\/business\/2021\/08\/23\/key-players-such-as-phathom-pharmaceuticals-and-others-are-developing-therapies-to-enhance-treatment-modalities-in-the-zollinger-ellison-syndrome-market\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipsnews.net\/business\/"},{"@type":"ListItem","position":2,"name":"Key players such as Phathom Pharmaceuticals and others are developing therapies to enhance treatment modalities in the Zollinger-Ellison Syndrome market"}]},{"@type":"WebSite","@id":"https:\/\/ipsnews.net\/business\/#website","url":"https:\/\/ipsnews.net\/business\/","name":"Business","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipsnews.net\/business\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee","name":"iCrowdNewswire","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","caption":"iCrowdNewswire"},"sameAs":["https:\/\/heymuse.com\/ips"],"url":"https:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/130335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/users\/291"}],"replies":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/comments?post=130335"}],"version-history":[{"count":1,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/130335\/revisions"}],"predecessor-version":[{"id":130336,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/130335\/revisions\/130336"}],"wp:attachment":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/media?parent=130335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/categories?post=130335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/tags?post=130335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}